Jefferies raised the firm’s price target on Cardinal Health (CAH) to $220 from $190 and keeps a Buy rating on the shares. The firm notes the company delivered a strong Q3, raising guidance and, most importantly, delivering strong core Pharma numbers against a low buy-side bar. Despite the raise, FY26 guidance still looks conservative to Jefferies, given the strong Q1 performance even after accounting for modest accretion from the now closed Solaris acquisition. The firm remains bullish, as Cardinal Health continues to execute on its strategic priorities with line of sight to achieve its +12%-14% EPS LRP.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAH:
- Cencora price target raised to $345 from $315 at BofA
- McKesson price target raised to $900 from $850 at BofA
- Cardinal Health price target raised to $225 from $183 at TD Cowen
- Cardinal Health Reports Strong Earnings and Raises Guidance
- Cardinal Health price target raised to $220 from $190 at Evercore ISI